What's New
Ferrer Doses First Participant in Phase 2 Study for PSP Treatment
Pharmaceutical company Ferrer announced that it has dosed the first participant in the PROSPER phase 2 clinical trial for an experimental treatment for progressive supranuclear palsy. The ongoing trial seeks…
Persons with FTD Advisory Council Special Article: Holiday Madness
This article was written by a person with FTD to highlight the challenges of dealing with the holidays with an FTD diagnosis. AFTD hopes care partners and those diagnosed can…
All in the Family to end FTD: Colonial Electric’s Food for Thought Event Clears More than $1 Million Since Inception
AFTD Board alumnus, Steve Bellwoar, has raised more than $1 million to drive AFTD’s mission in memory of his mother. Patricia “Trish” Bellwoar died in 2021 after living with FTD…
A Conversation with a Neurologist at Denali Therapeutics
Recently, AFTD had a conversation with members of the Denali Therapeutics team, including Dr. Richard Tsai, to provide insights into their work to develop a therapeutic with Takeda to treat…
Thanks to Generosity of AFTD Ambassador, Californians Receive Crucial Financial Help
Terry Walter, an AFTD Ambassador in California and Nevada, has been a force for positive change and support since 2008, when she began volunteering for AFTD. Over the years she…
Protected: A Conversation with a Neurologist at Denali Therapeutics
There is no excerpt because this is a protected post.
AFTD Care Partner Learning Series Webinar: Navigating the Holidays with an FTD Diagnosis
The changes brought on by an FTD diagnosis can make navigating the holidays difficult. The routine changes of travel, large crowds, and busy days can lead to unsuccessful holiday experiences.…
Young Caregiver Talks About Finding Support Amid FTD Journey on Dementia UK Podcast
A young FTD caregiver named Lizzie discussed the grief, uncertainty, and unexpected responsibilities she faced as she cared for her father — all while navigating the natural changes of young…
Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC
Shana Dodge, PhD, AFTD’s Director of Research Engagement and Meghan Buzby, MBA, AFTD’s Director of Advocacy and Volunteer Engagement attended the National Organization for Rare Disorders (NORD) Breakthrough Summit, held…
GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP
South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a clinical trial evaluating a drug for PSP. While the drug failed to show…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)